Literature DB >> 3752974

Metabolism of ribavirin in respiratory syncytial virus-infected and uninfected cells.

D F Smee, T R Matthews.   

Abstract

The metabolism of ribavirin to its mono-, di-, and triphosphate derivatives was examined in uninfected and respiratory syncytial virus-infected cells. The degree of phosphorylation was dose dependent upon extracellular ribavirin concentration. The major species formed was the triphosphate, with mono- and diphosphates being approximately 12 and 4% of the triphosphate, respectively. Amounts of triphosphate formed in infected cells were up to 2.6-fold greater than those in uninfected cells. Upon drug removal, ribavirin triphosphate degradation was very rapid, with decay half-lives of 70 to 100 min. Actinomycin D inhibited triphosphate production and also neutralized the antiviral effect of ribavirin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3752974      PMCID: PMC176447          DOI: 10.1128/AAC.30.1.117

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  The broad spectrum antiviral agent ribavirin inhibits capping of mRNA.

Authors:  B B Goswami; E Borek; O K Sharma; J Fujitaki; R A Smith
Journal:  Biochem Biophys Res Commun       Date:  1979-08-13       Impact factor: 3.575

2.  Metabolism of 5-amino-1-beta-D-ribofuranosylimidazole-4-carboxamide and related five-membered heterocycles to 5'-triphosphates in human blood and L5178Y cells.

Authors:  T P Zimmerman; R D Deeprose
Journal:  Biochem Pharmacol       Date:  1978-03-01       Impact factor: 5.858

3.  Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate.

Authors:  B Eriksson; E Helgstrand; N G Johansson; A Larsson; A Misiorny; J O Norén; L Philipson; K Stenberg; G Stening; S Stridh; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

4.  Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line.

Authors:  R C Willis; D A Carson; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

5.  The relationship between the metabolism of ribavirin and its proposed mechanism of action.

Authors:  J P Miller; L J Kigwana; D G Streeter; R K Robins; L N Simon; J Roboz
Journal:  Ann N Y Acad Sci       Date:  1977-03-04       Impact factor: 5.691

6.  In vivo inhibition of respiratory syncytial virus by ribavirin.

Authors:  J F Hruska; P E Morrow; S C Suffin; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

7.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

8.  Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent.

Authors:  D G Streeter; J T Witkowski; G P Khare; R W Sidwell; R J Bauer; R K Robins; L N Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1973-04       Impact factor: 11.205

9.  Metabolism of acyclovir in virus-infected and uninfected cells.

Authors:  P A Furman; P de Miranda; M H St Clair; G B Elion
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

10.  Inhibition of Sindbis virus replication in Aedes albopictus cells by virazole (ribavirin) and its reversal by actinomycin: a correction.

Authors:  F Malinoski; V Stollar
Journal:  Virology       Date:  1980-04-30       Impact factor: 3.616

View more
  14 in total

1.  Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.

Authors:  Liviawati S Wu; Joseph E Rower; James R Burton; Peter L Anderson; Kyle P Hammond; Fafa Baouchi-Mokrane; Gregory T Everson; Thomas J Urban; David Z D'Argenio; Jennifer J Kiser
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

Review 2.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

Review 3.  Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Authors:  Katherine L B Borden; Biljana Culjkovic-Kraljacic
Journal:  Leuk Lymphoma       Date:  2010-10

4.  Visna virus as an in vitro model for human immunodeficiency virus and inhibition by ribavirin, phosphonoformate, and 2',3'-dideoxynucleosides.

Authors:  K B Frank; P A McKernan; R A Smith; D F Smee
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 5.  Antiviral therapy with small particle aerosols.

Authors:  V Knight; B Gilbert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

6.  ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system.

Authors:  Minami Iikura; Tomomi Furihata; Misa Mizuguchi; Miki Nagai; Masanori Ikeda; Nobuyuki Kato; Akihito Tsubota; Kan Chiba
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

7.  Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin.

Authors:  Nirav R Shah; Amanda Sunderland; Valery Z Grdzelishvili
Journal:  PLoS One       Date:  2010-06-22       Impact factor: 3.240

8.  Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver.

Authors:  Chin-Chung Lin; David Lourenco; Guifen Xu; Li-Tain Yeh
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Ribavirin targets eIF4E dependent Akt survival signaling.

Authors:  Keith Tan; Biljana Culjkovic; Abdellatif Amri; Katherine L B Borden
Journal:  Biochem Biophys Res Commun       Date:  2008-08-14       Impact factor: 3.575

10.  Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells.

Authors:  Donald F Smee; Brett L Hurst; Hiroyuki Egawa; Kazumi Takahashi; Takumi Kadota; Yousuke Furuta
Journal:  J Antimicrob Chemother       Date:  2009-07-29       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.